Clinical trials: Blood Disease
Hepatitis C
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
The purpose of this research study is to find out the effect of the investigational drug NOV-205 on the level of hepatitis C virus in the blood and whether NOV-205 is well-tolerated at different doses when taken by subjects with…
- Trial name
- NOV-205 (NCT01058512)
- Testing
- NOV-205
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cellectar Biosciences, Inc.
B-cell Chronic Lymphocytic Leukemia
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to provide early access to Ibrutinib treatment for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and collect additional safety data while the medication is not…
- Trial name
- NCT02437019
- Testing
- PCI-32765 (Ibrutinib)
- Where
- 6 sites in Brazil
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Acute Myeloid Leukemia (AML)
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-CD123 in patients with hematologic and…
- Trial name
- NCT04230265
- Testing
- Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP)
- Where
- 10 sites in Germany, Netherlands
- Volunteers
- 32 people
- Sponsor
- AvenCell Europe GmbH
Acute Leukemia, Chronic Leukemia
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.
- Conditions
- Acute Leukemia, Chronic Leukemia, Multiple Myeloma, Hodgkin's Lymphoma
- Trial name
- NCT00273936
- Testing
- AVN-944 capsules for oral administration
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
AML, Adult
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
This is a first-in-human, dose-escalation and dose-expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of STI-8591 in subjects with advanced AML who have signed an informed consent…
- Trial name
- NCT05947344
- Testing
- STI-8591
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
Hepatitis B, Chronic
Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
Bile acids regulating farnesoid X receptor (FXR) interact with hepatitis B virus replication. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B.
- Trial name
- NCT03272009
- Testing
- EYP001a, Entecavir, peg-interferon alfa-2a
- Where
- 9 sites in Australia, Netherlands and 2 more
- Volunteers
- 73 people
- Sponsor
- Enyo Pharma
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL)
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
This study is an open-label, controlled, multicenter, international, Phase III, randomized study of transplantation of NiCord® versus transplantation of one or two unmanipulated, unrelated cord blood units in patients with acute…
- Conditions
- Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02730299
- Testing
- NiCord® (omidubicel), Cord Blood Unit
- Where
- 52 sites in United States, Brazil and 8 more
- Volunteers
- 125 people
- Sponsor
- Gamida Cell ltd
Hemophilia B
RIXUBIS Drug Use-Result Survey (Japan)
The purpose of this survey is to understand the following items observed in the actual clinical use of RIXUBIS. 1. Unexpected adverse drug reactions 2. Occurrence of adverse drug reactions in the actual clinical use 3.
- Trial name
- NCT02937831
- Testing
- RIXUBIS
- Where
- 5 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Baxalta now part of Shire
Myelodysplastic Syndromes, Anemia
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
The purpose of this study is to evaluate the effectiveness of PROCRIT (Epoetin alfa) 80,000 Units given once weekly or 80,000 Units given once every two weeks in anemic patients with Low- or Intermediate-1 risk Myelodysplastic…
- Trial name
- NCT00446602
- Testing
- Epoetin alfa
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
HIV Infections
A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
- Trial name
- NCT00002195
- Testing
- Amprenavir, Lamivudine, Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 290 people
- Sponsor
- Glaxo Wellcome
Cancer of the Pancreas, Pancreatic Cancer
Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)
This is a case-control study to clinically validate the performance of PancreaSure, a protein biomarker test, to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired…
- Conditions
- Cancer of the Pancreas, Pancreatic Cancer, Pancreas Neoplasms, Pancreatic Carcinoma Stage I
- Trial name
- VERIFI (NCT06947395)
- Testing
- PancreaSure
- Where
- 6 sites in United States
- Volunteers
- 386 people
- Sponsor
- Immunovia, Inc.
Degenerative Osteoarthritis, Defect of Articular Cartilage
Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect
This is a long term follow-up study to investigate the safety and efficacy of CARTISTEM®, human umbilical cord blood-derived mesenchymal stem cells, in repair of cartilage injury or defects, compared with microfracture.
- Trial name
- NCT01626677
- Testing
- CARTISTEM, Microfracture
- Where
- 10 sites in South Korea
- Volunteers
- 103 people
- Sponsor
- Medipost Co Ltd.
Infection, Human Immunodeficiency Virus
A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects
The purpose of the study is to determine the effect of multiple doses of BMS-955176 on the QT interval corrected with Fridericia's method (QTcF) in healthy subjects.
- Trial name
- NCT02576119
- Where
- United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Sickle Cell Disease, Umbilical Cord Blood
US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease
The application of experimental hematopoietic cell transplantation (HCT) therapy in sickle-cell disease (SCD) must strike a balance between the underlying disease severity and the possibility of a direct benefit of the treatment…
- Conditions
- Sickle Cell Disease, Umbilical Cord Blood, Hematopoietic Cell Proliferation
- Trial name
- NCT04594031
- Testing
- ECT-001-CB (UM171-Expanded Cord Blood Transplant)
- Where
- 2 sites in United States
- Sponsor
- ExCellThera inc.
Hypertension, Vascular Diseases
Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
An international, multi-center, prospective, blinded, randomized, controlled trial. The objective is to demonstrate that catheter-based renal denervation is an effective and safe treatment for uncontrolled hypertension.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- HTN-4 (NCT01972139)
- Testing
- Renal Denervation using the Symplicity Renal Denervation System, Renal Angiography
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Medtronic Vascular
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 or 24 weeks in adults with genotype 1 or 4…
- Trial name
- NCT02301936
- Testing
- LDV/SOF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Gilead Sciences
HCV Infection
Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
The purpose of this study is to evaluate the effect of food on pharmacokinetics, safety and tolerability of an experimental Hepatitis C Virus (HCV) protease inhibitor with ritonavir in healthy volunteers.
- Trial name
- NCT00909311
- Testing
- ABT-450, ritonavir
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Abbott
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH.
- Trial name
- NCT03053102
- Testing
- Danicopan
- Where
- 5 sites in Italy, New Zealand and 2 more
- Volunteers
- 10 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hypertension
Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
This observational study is designed to evaluate the effects of Twynsta tablets with life style modifications on blood pressure, quality of life, and other risk factors in Korean patients with hypertension in a routine clinical…
- Trial name
- NCT01316419
- Testing
- Telmisartan, amlodipine
- Where
- 55 sites in South Korea
- Volunteers
- 2,089 people
- Sponsor
- Boehringer Ingelheim
Lymphoma, B-Cell, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies.
- Conditions
- Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT03162536
- Testing
- Nemtabrutinib
- Where
- 10 sites in United States
- Volunteers
- 190 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.